Table 2 Distribution of the study parameters in all PET/CT examinations (n = 470) depending on the BAT activity.

Parameter (patient n)^a	BAT activity (n or mean ± SD )			Regression (p-value)
Parameter (patient n)^a	None	Low	High	Univariate	Multivariate^b
Total	415	30	25	N/A
Active BAT depots (range)	0	2–6	4–6	N/A
SUVmean of the active BAT depots	N/A	1.8 ± 0.2	2.7 ± 0.6	N/A
Age (years, n = 469)	53 ± 18	37 ± 14	28 ± 13	< 0.001*	< 0.001*
BMI (kg/m², n = 459)	25.7 ± 5.3	24.4 ± 5.0	22.6 ± 3.2	0.002*	0.04*
Sex (females)	186	21	15	0.01*	0.04*
Lymphoma group
Mature B-cell lymphoma	211	9	7	0.02*	0.13
Hodgkin lymphoma	170	21	15
Mature T-cell lymphoma	14	0	2
Other lymphoma	20	0	1
Season of PET
Spring	112	7	8	0.04*	0.04*
Summer	114	6	3
Autumn	98	9	2
Winter	91	8	12
Disease activity (n = 422)	226	12	13	0.58
No preceding therapy	141	10	7	0.83
Radiotherapy	41	3	4	0.62
ABVD regimen	42	8	5	0.01*	0.52
CHOP/CHLIP regimen	92	4	5	0.51
BEACOPP regimen	49	6	5	0.23
Rituximab	111	5	4	0.25
Cytarabine	32	1	3	0.48
Steroids	200	13	12	0.88
Beta-receptor therapy (n = 462)
Inhibition	61	0	0	0.03*	0.02*
No therapy	340	30	24
Beta-receptor agonist	6	0	1
Thyroid dysfunction (n = 458)
Hypothyroidism	66	1	4	0.24
Euthyroidism	315	28	21
Hyperthyroidism	22	1	0
Hyperlipidemia (n = 457)	43	1	1	0.26
Diabetes mellitus (n = 464)	74	0	0	0.003*	0.004*
Hypertension (n = 463)	103	3	1	0.01*	0.03*
Prior cancer (n = 463)	37	0	0	0.07

*Significant, p value of < 0.05, ^apatient number for evaluation of this parameter if divergent from the total patient number, ^bonly significant parameters of the univariate analyses were included.
BAT brown adipose tissue, SUVmean mean standardized uptake value, ABVD regimen doxorubicin, bleomycin, vinblastine, dacarbazine, CHOP/CHLIP regimen cyclophosphamide, doxorubicin, conventional/liposomal vincristine, steroids, BEACOPP regimen bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and steroids, N/A not applicable.

Search